SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
Endocrinology and Metabolism · 31.12.2025 · 40 (6) · 851-865
DOI: 10.3803/enm.2025.2786 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.12.2025. Verfasst von Seung Wan Noh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science and Technology, Gachon Advanced Institute for Health Science and Technology, Gachon University, Incheon, Korea. Hauptthemen laut MEDLINE: Fatty Liver, Metabolic Diseases, Sodium-Glucose Transporter 2 Inhibitors, Liver. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Gachon University.
Abstract (Originalsprache)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as paradigm-shifting therapeutics that extend beyond glycemic regulation, to conferring profound hepatometabolic benefits. This review delineates the multifaceted mechanisms underlying metabolic dysfunction-associated steatotic liver disease (MASLD), with an emphasis on systemic metabolic remodeling, mitochondrial protection, and intracellular calcium restoration. By promoting glucosuria-induced energy depletion, SGLT2 inhibition alleviates insulin resistance, suppresses hepatic lipogenesis, and activates adenosine monophosphate-activated protein kinase (AMPK)–sirtuin 1 (SIRT1)–peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α pathways that reprogram hepatocellular metabolism toward achieving lipid oxidation and autophagy. Mechanistically, SGLT2 inhibitors restore intracellular Ca2+ homeostasis via sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) activation, mitigating endoplasmic reticulum (ER) stress and normalizing Ca2+–phosphoinositide (PIP)–protein kinase B (AKT) signaling, collectively reinforcing insulin responsiveness and ER-mitochondrial crosstalk. Clinically, these effects translate into consistently reducing hepatic fat, aminotransferases, and fibrosis markers in both diabetic and nondiabetic patients with MASLD. Furthermore, SGLT2 inhibitors uniquely integrate renal energy regulation with hepatic resilience through the Ca2+–PIP–SERCA axis, positioning them as prototype systemic modulators of metabolic homeostasis. Future translational efforts should refine patient stratification using metabolomic and Ca2+-imaging biomarkers to delineate therapeutic responders and advance next-generation SGLT2 analogs targeting Ca2+-dependent metabolic signaling. Collectively, SGLT2 inhibitors represent a new metabolic therapeutic class that unify glucose, lipid, and Ca2+ regulation to restore hepatocellular functions in metabolic liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Science and Technology, Gachon Advanced Institute for Health Science and Technology, Gachon University, Incheon, Korea.
- Department of Physiology, Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Gachon University
Zitieren
APA
Noh, S. W., Ryu, H. S., Kim, Y. H., & Oh, B. C. (2025). SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration. Endocrinology and Metabolism, 40(6), 851-865. https://doi.org/10.3803/enm.2025.2786
Vancouver
Noh SW, Ryu HS, Kim YH, Oh BC. SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration. Endocrinology and Metabolism. 2025;40(6):851-865. doi:10.3803/enm.2025.2786
BibTeX
@article{Noh2025,
author = {Noh, Seung Wan and Ryu, Han Sol and Kim, Yong-Ho and Oh, Byung-Chul},
title = {SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration},
journal = {Endocrinology and Metabolism},
year = {2025},
volume = {40},
number = {6},
pages = {851--865},
doi = {10.3803/enm.2025.2786}
}
EUVIMED